Sutro Biopharma
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 324
- Market Cap
- $392.6M
- Website
- http://www.sutrobio.com
- Introduction
Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with Relapsed/Refractory CBFA2T3::GLIS2 AML
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06679582
- Locations
- 🇺🇸
Childrens Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Childrens National Hospital, Washington, District of Columbia, United States
🇺🇸Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
Study to Investigate Luveltamab Tazevibulin in Adults with Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Lung CancerLung Cancer Non-Small Cell Stage IIIBLung Cancer MetastaticLung Cancer, Non-small CellLung Cancer, Nonsmall CellLung Cancer Non-small Cell Stage IV
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT06555263
- Locations
- 🇺🇸
Tampa General Hospital, Tampa, Florida, United States
🇺🇸HealthPartners Cancer Research Center, St. Paul, Minnesota, United States
🇺🇸Florida Cancer Specialists, Lake Mary, Florida, United States
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
- Conditions
- Ovarian CancerEpithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerPlatinum-resistant Ovarian Cancer
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT05870748
- Locations
- 🇺🇸
Texas Oncology, Dallas, Texas, United States
🇺🇸Ohio State University Center, Columbus, Ohio, United States
🇺🇸Baptist Health South Florida (BHSF) - Miami Cancer Institute, Miami, Florida, United States
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
- Conditions
- Ovarian CancerOvarian CarcinomaOvary CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT05200364
- Locations
- 🇺🇸
University of South Florida,, Tampa, Florida, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
- Conditions
- Endometrioid AdenocarcinomaOvarian CancerOvarian CarcinomaPrimary Peritoneal CarcinomaOvary CancerEndometrial CancerFallopian Tube Cancer
- Interventions
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT03748186
- Locations
- 🇺🇸
Miami Cancer Institue, Baptist Health South Florida, Miami, Florida, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸Minnesota Oncology Hematology, Minneapolis, Minnesota, United States
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
- Conditions
- Indolent LymphomaMultiple MyelomaDiffuse Large B Cell LymphomaNon Hodgkin LymphomaFollicular LymphomaB Cells--TumorsB-cell LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT03424603
- Locations
- 🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States